Nina R. Schooler, PhD

The Patient Perspective on Tardive Dyskinesia

April 29, 2026

Patients’ perspectives on their experiences with tardive dyskinesia provide critical insights that go beyond the information provided by clinical assessments.

Nina R. Schooler

Commentary

Functional Outcomes of an Antipsychotic in Schizophrenia: Generalizable or Specific Effect?

March 1, 2022

This commentary takes a closer look at Correll and colleagues’ findings on functional outcomes with brexpiprazole.

Nina R. Schooler

Original Research

Early Phase Schizophrenia and LAI

April 23, 2019

Read a study examining if patients in the early phase of schizophrenia would accept LAI antipsychotic treatment.

John M. Kane, Christoph U. Correll, Delbert G. Robinson, et al

Original Research

Clozapine and Risperidone in Moderately Refractory Schizophrenia: A 6-Month Randomized Double-Blind Comparison

May 25, 2016

Stephen R. Marder, Daniel Umbricht, John M. Kane, et al

Original Research

The RAISE: First-Episode Psychosis

March 25, 2015

Read an article describing The RAISE Early Treatment Program for First-Episode Psychosis, the background and study design of the program.

Jean Addington, John M. Kane, Christoph U. Correll, et al

Original Research

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

December 5, 2014

Ibrahim Turkoz, Jean-Pierre Lindenmayer, David P. Walling, et al

Original Research

Maintenance Treatment With Long-Acting Injectable Risperidone in First-Episode Schizophrenia: A Randomized Effectiveness Study

August 7, 2012

Peter J. Weiden, Nina R. Schooler, Jeremy C. Weedon, et al

Commentary

Can We Incorporate Psychosocial Treatment Interventions Into Psychopharmacology Clinical Trials?

July 15, 2012

Nina R. Schooler

Article

New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting: A Great Opportunity for Early Career Psychiatrists

April 15, 2012

John M. Kane, Bruce J. Kinon, William Z. Potter, et al

Original Research

Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres: An Open-Label, Randomized Controlled Trial

March 6, 2012

T. Scott Stroup, Joseph P. McEvoy, Nina R. Schooler, et al

NCDEU Festschrift

Jonathan O. Cole, MD (1925-2009): Innovator in Clinical Psychopharmacology and of the ECDEU/NCDEU Tradition

March 15, 2011

Nina R. Schooler

Original Research

A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder

May 15, 2010

Cynthia A. Bossie, Ibrahim Turkoz, Jean-Pierre Lindenmayer, et al

The Patient Perspective on Tardive Dyskinesia

Functional Outcomes of an Antipsychotic in Schizophrenia: Generalizable or Specific Effect?

Early Phase Schizophrenia and LAI

Clozapine and Risperidone in Moderately Refractory Schizophrenia: A 6-Month Randomized Double-Blind Comparison

The RAISE: First-Episode Psychosis

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

Maintenance Treatment With Long-Acting Injectable Risperidone in First-Episode Schizophrenia: A Randomized Effectiveness Study

Can We Incorporate Psychosocial Treatment Interventions Into Psychopharmacology Clinical Trials?

New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting: A Great Opportunity for Early Career Psychiatrists

Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres: An Open-Label, Randomized Controlled Trial

Jonathan O. Cole, MD (1925-2009): Innovator in Clinical Psychopharmacology and of the ECDEU/NCDEU Tradition

A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder

ELSEWHERE:

FOLLOW US:

Nina R. Schooler, PhD

The Patient Perspective on Tardive Dyskinesia

Functional Outcomes of an Antipsychotic in Schizophrenia: Generalizable or Specific Effect?

Early Phase Schizophrenia and LAI

Clozapine and Risperidone in Moderately Refractory Schizophrenia: A 6-Month Randomized Double-Blind Comparison

The RAISE: First-Episode Psychosis

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

Maintenance Treatment With Long-Acting Injectable Risperidone in First-Episode Schizophrenia: A Randomized Effectiveness Study

Can We Incorporate Psychosocial Treatment Interventions Into Psychopharmacology Clinical Trials?

New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting: A Great Opportunity for Early Career Psychiatrists

Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres: An Open-Label, Randomized Controlled Trial

Jonathan O. Cole, MD (1925-2009): Innovator in Clinical Psychopharmacology and of the ECDEU/NCDEU Tradition

A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder

Insightful. Evidence-based. Human-centered.

Subscribe to readmore articles

Subscribe to read
more articles